Multiple Myeloma Awareness Month

The AACR is hosting a scientific conference to broaden understanding of multiple myeloma and develop better treatments.
multiple myeloma awareness month

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell important for a healthy immune system. Over time, myeloma cells collect in the bone marrow, forming tumors in many of the body’s bones. These tumors may keep the bone marrow from making enough healthy blood cells and weaken the bone. 

While the causes of multiple myeloma are not fully understood, it is more common in older people, especially men, and African Americans. Some common symptoms include bone pain, weakness or fatigue, weight loss, frequent infections, and frequent urination. 

The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program estimates that more than 32,270 people living in the United States were diagnosed with multiple myeloma in 2020 and that 12,830 died of the disease.

March is Multiple Myeloma Awareness Month.

What is the AACR Doing in This Area?

In April 2021, AACR will present a virtual special conference on myeloma. This virtual meeting will be the first AACR conference focused on myeloma and will discuss the genomics and epigenetics of myeloma, disease progression, and treatment options in hopes of improving clinical outcomes., Learn more here.

The AACR has recently awarded a research grant to an investigator pursuing promising research related to multiple.

Julia Frede, PhD, a postdoctoral fellow at the Dana Farber Cancer Institute was awarded a two-year AACR-Amgen Fellowship in Clinical/Translational Cancer Research. Dr. Frede’s project seeks to define therapeutic approaches that can overcome therapy resistance in patients with multiple myeloma by delineating changes in functional states which can be targeted. She is performing RNA sequencing of single myeloma cells in longitudinal samples from patients with relapsed/refractory myeloma to analyze and investigate differentiation state changes.

“The [fellowship] gives me the opportunity to pursue my research investigating transcriptional heterogeneity and epigenetic plasticity in myeloma,” Dr. Freda.